Frequency News and Research

RSS

AMA's National Health Insurer Report Card helps improve claims processing performance

The American Medical Association today announced that one in five medical claims are processed inaccurately by health insurers, according to the AMA's third annual check-up of the nation's commercial health insurers and the systems they use to manage and pay claims. This was the key finding of the AMA's 2010 National Health Insurer Report Card, which for the first time, benchmarked the overall claims processing accuracy of the nation's largest health insurers.

15 Jun 2010

CT angiography not necessary in patients suspected with pulmonary embolism

A new study suggests that computed tomography (CT) angiography might be unnecessary in many patients suspected of having pulmonary embolism (PE), based on the results of risk assessment analysis. PE risk assessment could help reduce radiation exposure and costs associated with CT angiography. The results of the study appear in the online edition and August print issue of the journal Radiology.

15 Jun 2010

SCS may be able to modulate PD symptoms: Study

A new study from Rhode Island Hospital indicates that spinal cord stimulation may be able to modulate Parkinson's disease symptoms. The lead author will present the findings at the 2010 American Society for Stereotactical and Functional Neurosurgery Biennial Meeting, June 14-16 in New York City.

15 Jun 2010

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today introduced Medidata Grants Manager 3.0, the newest version of its trial budgeting application in use today by many of the innovative clinical research sponsors in the life sciences industry. Now offered as a web-based solution, Grants Manager 3.0 enables users to build clinical trial grant budgets and benchmark them against Medidata's unique PICAS database of negotiated trial costs without the need to install software.

14 Jun 2010

Children get MRI tests for reasons unrelated to benign anomalies: Study

Pediatricians whose patients undergo "routine" brain MRIs need a plan to deal with findings that commonly reveal unexpected-but-benign anomalies that are unlikely to cause any problem, reports a research team led by Johns Hopkins Children's Center investigators.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Medicare drug spending varies by region, does not offset other medical costs

A study has found that Medicare spending on drugs varies significantly in different regions, and that increased drug spending isn't offset by lower spending on hospital care, doctors visits and other health services, HealthDay/Bloomberg Businessweek reports.

11 Jun 2010

Researchers to provide real-time analyses on potential disease threats during World Cup

Two Canadian researchers will be keeping a close eye on what hundreds of thousands of soccer fans take to the World Cup in South Africa _ and what they potentially bring home.

11 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

People who smoke immediately after waking may be at risk for lung cancer: Study

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Medicalis launches Coordinated Imaging Care Solution

Medicalis Corporation announced today the launch of its Coordinated Imaging Care Solution (CICS), an integrated technology platform that provides clinical decision support, e-ordering, and extensive quality tracking that enables comparative effectiveness in medical imaging. The solution provides the broadest set of quality indicators specifically related to medical imaging available.

9 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

HHS Secretary statement on new study that underscores urgency for reducing HAIs in ASCs

"Today, the Journal of the American Medical Association published a new study from the Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services, which underscored the urgency behind the Obama Administration's efforts to reduce healthcare-associated infections.

9 Jun 2010

FDA should implement risk-based approach to tackle food safety problems: Report

The U.S. Food and Drug Administration's abilities to discover potential threats to food safety and prevent outbreaks of foodborne illness are hampered by impediments to efficient use of its limited resources and a piecemeal approach to gathering and using information on risks, says a new report by the Institute of Medicine and National Research Council.

9 Jun 2010

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.

8 Jun 2010

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Nighttime noise from nearby road traffic, passing trains and overhead planes disturbs sleep and impairs morning performance, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.

8 Jun 2010

Frequency News and Research

AMA's National Health Insurer Report Card helps improve claims processing performance

CT angiography not necessary in patients suspected with pulmonary embolism

SCS may be able to modulate PD symptoms: Study

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Children get MRI tests for reasons unrelated to benign anomalies: Study

ARBs increase risk of cancer: Study

National MS Society commits over $2.4M to support 7 CCSVI research projects

Medicare drug spending varies by region, does not offset other medical costs

Researchers to provide real-time analyses on potential disease threats during World Cup

Nativis awarded patents in Japan, China, India for drug signal technology

People who smoke immediately after waking may be at risk for lung cancer: Study

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

Medicalis launches Coordinated Imaging Care Solution

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

HHS Secretary statement on new study that underscores urgency for reducing HAIs in ASCs

FDA should implement risk-based approach to tackle food safety problems: Report

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News